IRAK4 polyclonal Antibody | BS7963

IRAK4 polyclonal Antibody | BS7963 | Gentaur UK, US & Europe Distribution

Host: Rabbit

Reactivity: Human,Mouse,Rat

Application: WB IHC

Application Range: WB: 1:500~1:2000 IHC: 1:50~1:200

Background: Interleukin-1 receptor (IL1R) -associated kinases (IRAKs) are important mediators in the signal transduction of Toll-like receptor (TLR) and IL1R family members, collectively referred to as TIRs. IRAK family members include two active kinases, IRAK-1 and IRAK-4, and two inactive kinase, IRAK-2 and IRAK-M. Binding of IL-1 to its cognate receptor results in the activation of the NFkB signaling pathway and MAP kinase pathways. IRAK-4 appears to act upstream of other IRAKs and phosphorylates IRAK-1 on threonine 387. It is highly expressed in liver and kidney tissues, but also displays a wide, low level of expression in other tissues. IRAK-4 is an essential component of innate immunity. Deficiency of IRAK-4 leads to recurrent bacterial infections and profound hyporesponsiveness to LPS and IL-1. Therefore, IRAK-4 may be a potential target for therapeutic drug design.

Storage & Stability: Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze-thaw cycles.

Specificity: IRAK4 polyclonal Antibody detects endogenous levels of IRAK4 protein.

Molecular Weight: ~ 52 kDa

Note: For research use only, not for use in diagnostic procedure.

Alternative Names: IL-1 receptor-associated kinase 4; Interleukin 1 receptor associated kinase 4 mutant form 1; Interleukin-1 receptor-associated kinase 4; Interleukin1 receptor associated kinase 4; IPD1; IRAK 4; IRAK-4; IRAK4; IRAK4 mutated form 1; IRAK4_HUMAN; LOC 51135; NY REN 64; NY REN 64 antigen; NY-REN-64; REN64; Renal carcinoma antigen NY-REN-64;

Immunogen: Recombinant full length Human IRAK4.

Conjugate: Unconjugated

Modification: Unmodification

Purification & Purity: The Antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen and the purity is > 95% (by SDS-PAGE) .

Pathway: